SF
CMIIU

Scott Ferguson’s CM Life Sciences II Inc. Unit CMIIU Stock Holding History

Scott Ferguson’s Portfolio CMIIU Stock Details CMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-800,000
Closed -$10.2M – 30
2021
Q1 		$10.2M Buy
+800,000
New +$10M 0.28% 19

Other funds holding CMIIU

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
TCIM
TOMS Capital Investment Management New York $4.67B AUM 83.55% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return

Scott Ferguson's CMIIU Position: Q2 2021 in Review

Scott Ferguson sold out of CM Life Sciences II Inc. Unit (CMIIU) in Q2 2021, closing a stake of 800,000 shares — an estimated $10.2M sold.

Scott Ferguson first reported a position in CMIIU in Q1 2021 and held it in 1 quarter. The position peaked at $10.2M in Q1 2021. 38 funds tracked by Wall St. Rank hold CMIIU as of Q2 2021.

  • Scott Ferguson reported no remaining CM Life Sciences II Inc. Unit position as of Q2 2021 after selling out during the quarter.
  • Scott Ferguson sold 800,000 CM Life Sciences II Inc. Unit shares in Q2 2021, an estimated $10.2M.
  • Scott Ferguson first reported a position in CM Life Sciences II Inc. Unit in Q1 2021 and held it in 1 quarter.
  • Scott Ferguson's CM Life Sciences II Inc. Unit position peaked at $10.2M in Q1 2021.
  • 38 funds tracked by Wall St. Rank held CM Life Sciences II Inc. Unit as of Q2 2021.

Based on Sachem Head Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.